These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2278102)

  • 1. The 3-D structure of HIV-1 proteinase and the design of antiviral agents for the treatment of AIDS.
    Blundell TL; Lapatto R; Wilderspin AF; Hemmings AM; Hobart PM; Danley DE; Whittle PJ
    Trends Biochem Sci; 1990 Nov; 15(11):425-30. PubMed ID: 2278102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evaluation of non-viral substrates of the HIV protease as leads in the design of inhibitors for AIDS therapy.
    Tomasselli AG; Hui JO; Sawyer TK; Thaisrivongs S; Hester JB; Heinrikson RL
    Adv Exp Med Biol; 1991; 306():469-82. PubMed ID: 1812744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Virology/AIDS. A second front in virus chemotherapy].
    Fortschr Med; 1989 Apr; 107(13):15-6. PubMed ID: 2656439
    [No Abstract]   [Full Text] [Related]  

  • 4. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.
    Tsantrizos YS
    Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HIV-1 protease as a therapeutic target for AIDS.
    Debouck C
    AIDS Res Hum Retroviruses; 1992 Feb; 8(2):153-64. PubMed ID: 1540403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational drug design: the proteinase inhibitors.
    Wlodawer A
    Pharmacotherapy; 1994; 14(6 Pt 2):9S-20S. PubMed ID: 7885983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression, characterisation and mutagenesis of the aspartic proteinase from equine infectious anaemia virus.
    Powell DJ; Bur D; Wlodawer A; Gustchina A; Payne SL; Dunn BM; Kay J
    Eur J Biochem; 1996 Oct; 241(2):664-74. PubMed ID: 8917470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A series of penicillin derived C2-symmetric inhibitors of HIV-1 proteinase: synthesis, mode of interaction, and structure-activity relationships.
    Humber DC; Bamford MJ; Bethell RC; Cammack N; Cobley K; Evans DN; Gray NM; Hann MM; Orr DC; Saunders J
    J Med Chem; 1993 Oct; 36(21):3120-8. PubMed ID: 8230098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of molecular dynamics and free energy perturbation calculations in anti-human immunodeficiency virus drug design.
    McCarrick MA; Kollman P
    Methods Enzymol; 1994; 241():370-84. PubMed ID: 7854189
    [No Abstract]   [Full Text] [Related]  

  • 10. Structural mechanisms of HIV drug resistance.
    Erickson JW; Burt SK
    Annu Rev Pharmacol Toxicol; 1996; 36():545-71. PubMed ID: 8725401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examination of HIV-1 protease secondary structure specificity using conformationally constrained inhibitors.
    Kahn M; Nakanishi H; Chrusciel RA; Fitzpatrick D; Johnson ME
    J Med Chem; 1991 Dec; 34(12):3395-9. PubMed ID: 1766005
    [No Abstract]   [Full Text] [Related]  

  • 12. Exploring the antiviral activity of juglone by computational method.
    Vardhini SR
    J Recept Signal Transduct Res; 2014 Dec; 34(6):456-7. PubMed ID: 24846583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV protease: a novel chemotherapeutic target for AIDS.
    Huff JR
    J Med Chem; 1991 Aug; 34(8):2305-14. PubMed ID: 1875332
    [No Abstract]   [Full Text] [Related]  

  • 14. HIV-1 protease as a potential target for anti-AIDS therapy.
    Meek TD; Dreyer GB
    Ann N Y Acad Sci; 1990; 616():41-53. PubMed ID: 2078031
    [No Abstract]   [Full Text] [Related]  

  • 15. A new way of looking at aspartic proteinase structures: a comparison of pepsin structure to other aspartic proteinases in the near active site region.
    Andreeva NS; Bochkarev A; Pechik I
    Adv Exp Med Biol; 1995; 362():19-32. PubMed ID: 8540318
    [No Abstract]   [Full Text] [Related]  

  • 16. [The HIV proteinase--a target for antiviral agents].
    Grinde B; Jonassen TO
    Tidsskr Nor Laegeforen; 1996 Oct; 116(24):2908-11. PubMed ID: 8975409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure of HIV-1 protease with KNI-272: a transition state mimetic inhibitor containing allophenylnorstatine.
    Baldwin ET; Bhat TN; Gulnik S; Liu B; Kiso Y; Mitsuya H; Erickson JW
    Adv Exp Med Biol; 1995; 362():445-9. PubMed ID: 8540355
    [No Abstract]   [Full Text] [Related]  

  • 18. Designing drugs against heterogeneous targets.
    Freire E
    Nat Biotechnol; 2002 Jan; 20(1):15-6. PubMed ID: 11753347
    [No Abstract]   [Full Text] [Related]  

  • 19. The chronically infected cell as a target for the treatment of HIV infection and AIDS.
    Petteway SR; Lambert DM; Metcalf BW
    Trends Pharmacol Sci; 1991 Jan; 12(1):28-34. PubMed ID: 1672479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the HIV-protease in AIDS therapy: a current clinical perspective.
    Tomasselli AG; Heinrikson RL
    Biochim Biophys Acta; 2000 Mar; 1477(1-2):189-214. PubMed ID: 10708858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.